Responses
Clinical/translational cancer immunotherapy
Original research
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
Compose a Response to This Article
Other responses
No responses have been published for this article.